Luminex-based desensitization protocols: The university of wisconsin initial experience

Transplantation

Volumn 92, Issue 1, 2011, Pages 12-17

  Niederhaus, Silke V ^a   Muth, Brenda ^a   Lorentzen, David F ^b   Wai, Philip ^a   Pirsch, John D ^a   Samaniego Picota, Milagros ^c   Leverson, Glen E ^a   D'Alessandro, Anthony M ^a   Sollinger, Hans W ^a   Djamali, Arjang ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d 142 MFCB ^*  (United States)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Kidney transplant outcomes; Protocol biopsy

Indexed keywords

ALLOANTIBODY; BASILIXIMAB; BORTEZOMIB; CREATININE; DEXAMETHASONE; DONOR SPECIFIC ANTIBODY; GAMMAGARD SD; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD GROUP TYPING; CADAVER DONOR; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DIALYSIS; DRUG DOSE REDUCTION; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GRAFT FAILURE; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTILYMPHOCYTE SERUM; CLINICAL PROTOCOLS; FEMALE; HISTOCOMPATIBILITY TESTING; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WISCONSIN;

EID: 79959658661     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821c93bb     Document Type: Article

References (18)

1. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
2. Djamali A, Muth BL, Torrealba J, et al. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation. Clin Transpl 2009: 485.
3. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
4. Jordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
5. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.AmJ Transplant 2006; 6: 346.
6. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant 2004; 8: 535.
7. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
8. Magee CC, Felgueiras J, Tinckam K, et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: One center's experience. Transplantation 2008; 86: 96.
9. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
10. Muth B, Samaniego-Picota M, Lorentzen D, et al. Risk-factors forAMR and decreased kidney function in sensitized kidney transplant recipients followed-up for a median of 2 years. Am J Transplant 2010; 2010 WTC Abstract Book: Poster 608.
11. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079.
12. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536.
13. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? Front Biosci 2008; 13: 1396.
14. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
15. Patel AM, Pancoska C, Mulgaonkar S, et al. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
16. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
17. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403.
18. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.